Re: Summary of Proposed BETonMACE2 design and timelines
in response to
by
posted on
Feb 05, 2021 10:38PM
eGFR 30-44 aviod use, eGFR <30 contraindicated, HD/PD contraindicated. Mechanism of action depends on the kidneys abitilty to reduce glucose reabsorption and increase urinary glucose excetion. Of no use in ESRD